Verywell Health on MSN10h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
GlobalData on MSN22h
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
Frontiers1h
Understanding Adverse Effect in Myeloma Patients treated with T Cell Redirecting Immunotherapies
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
Verywell Health on MSN13h
Do Weight Loss Drugs Like Ozempic Affect Your Breast Health?
Ozempic breasts refer to changes in breast size or shape due to weight loss from GLP-1 drugs. Here’s how and why this side ...